Pharma Journalist -

Evotec AG announced that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating…
Read More...

Synlogic announced that it has dosed the first subject in its Phase 1/2a clinical trial of SYNB1618. SYNB1618 is a Synthetic Biotic medicine being developed for the treatment of…
Read More...

Astellas Pharma and Kite, a Gilead Company announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to…
Read More...

ProBioGen AG announced that it has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company,…
Read More...

Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the…
Read More...

During the past several years, many strains of bacteria have become resistant to existing antibiotics, and very few new drugs have been added to the antibiotic arsenal. To help…
Read More...

GE Healthcare is launching a ready-to-run factory-in-a-box to speed up the production of viral vector based therapeutics, including viral vector based vaccines, oncolytic viruses and…
Read More...

Merck announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The…
Read More...

SAMDI Tech, Inc. has partnered with Enamine to expand the number of molecules in their small molecule compound libraries. Through the partnership, SAMDI Tech will be able to offer its…
Read More...

Shire plc announces that it has entered into a definitive agreement with Servier S.A.S. to sell its Oncology business for $2.4 billion. Shire's Oncology business includes in-market…
Read More...